Periodontal disease as a modifiable contributor to NAFLD

Summaries 1 min 95

Font Size

Created On: 25/02/2026

Chronic periodontitis, Non-alcoholic fatty liver disease

Chronic periodontitis (CP) and non-alcoholic fatty liver disease (NAFLD) are two rapidly increasing chronic inflammatory disorders with significant global health effect.

See All

Key take away

Chronic periodontitis increases the risk and severity of NAFLD by driving systemic inflammation, gut barrier dysfunction, and oral–gut–liver axis disruption.

Background

Chronic periodontitis (CP) and non-alcoholic fatty liver disease (NAFLD) are two rapidly increasing chronic inflammatory disorders with significant global health effect. Growing clinical and mechanistic evidence suggests a strong connection between periodontal disease and NAFLD progression. The oral–gut–liver axis has emerged as a central pathway linking periodontal inflammation to hepatic steatosis, liver fibrosis, and metabolic dysfunction. This review explored the biological mechanisms and clinical implications connecting CP and NAFLD.

Method

A comprehensive analysis of epidemiological, interventional, and translational studies was executed to evaluate the link between periodontal disease severity, periodontal therapy, and NAFLD outcomes. Mechanistic pathways examined include oral and gut microbiome dysbiosis, systemic inflammatory cytokines, bacterial endotoxins, microbial metabolites (short-chain fatty acids, trimethylamine n-oxide), oxidative stress, insulin resistance, intestinal permeability, and microRNA-mediated immune-metabolic regulation.

Result

Accumulated evidence demonstrated that CP is independently linked with increased risk, greater severity, and faster progression of NAFLD. Oral dysbiosis, marked by overgrowth of periodontal pathogens, contributes to hepatic fat accumulation, chronic liver inflammation, and fibrosis through systemic dissemination of microbial products. Elevated inflammatory mediators impair gut barrier integrity, promote endotoxemia, and trigger hepatocellular injury. Additionally, microbial metabolites and oxidative stress pathways exacerbate insulin resistance and metabolic syndrome components, further accelerating NAFLD progression.

Emerging data indicate that microRNAs function as epigenetic regulators connecting periodontal inflammation, bone metabolism, and hepatic immune responses. While preliminary findings suggest periodontal treatment may minimize systemic inflammatory burden, high-quality longitudinal trials are needed to verify its impact on NAFLD clinical outcomes. Despite heterogeneity across studies, current evidence supports CP as a modifiable and clinically relevant risk factor in NAFLD pathogenesis.

Conclusion

CP and NAFLD are biologically interconnected through systemic inflammation, microbiome imbalance, metabolic dysregulation, and the oral–gut–liver axis. Integrating periodontal care into multidisciplinary NAFLD care strategies may improve liver health and cardiometabolic outcomes. Future research must prioritize microbiome-targeted interventions, personalized risk stratification, and preventive strategies to address these highly prevalent inflammatory ailments.